December 02, 2019

ABT-414 Shows no Overall Survival Benefit for Patients with Newly Diagnosed Glioblastoma

The interim analysis of the RTOG Foundation clinical trial RTOG 3508/AbbVie M13-813 (INTELLANCE-1) was not able to determine that the addition of the drug depatuximab mafodotin (depatux-m, formerly ABT-414), developed by AbbVie, could improve overall survival (OS) outcomes for patients with newly diagnosed glioblastoma (nGBM). Read more